MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 489.9% in May

Posted by Brian Himes on Jun 10th, 2026

MetaVia Inc. (NASDAQ:MTVA – Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 408,434 shares, a growth of 489.9% from the May 14th total of 69,235 shares. Based on an average daily volume of 21,957,148 shares, the days-to-cover ratio is presently 0.0 days. Currently, 8.0% of the shares of the stock are sold short.

MetaVia Price Performance

Shares of MetaVia stock traded up $0.07 during trading on Wednesday, hitting $1.96. The stock had a trading volume of 235,673 shares, compared to its average volume of 2,230,112. The firm’s fifty day simple moving average is $1.81 and its 200-day simple moving average is $3.69. The stock has a market cap of $10.11 million, a PE ratio of -0.38 and a beta of 0.92. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03.

MetaVia (NASDAQ:MTVA – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Analysts expect that MetaVia will post -2.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new stake in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent filing with the Securities and Exchange Commission. 1.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MTVA has been the subject of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research report on Friday, April 24th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of MetaVia in a research report on Monday, May 18th. Finally, Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.00.

View Our Latest Stock Report on MTVA

MetaVia Company Profile

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.